Middle East & Africa Endomyocardial Biopsy Devices Market Size and Forecast (2021

Description

List of Tables

The Middle East and Africa Endomyocardial Biopsy Devices Market is projected to increase from US$ 7,296.7 Thousand in 2025 to US$ 9,740.4 Thousand by 2034. The market is anticipated to grow at a CAGR of 3.3% during the period from 2026 to 2034.

Executive Summary and Middle East and Africa Endomyocardial Biopsy Devices Market Analysis

The Middle East endomyocardial biopsy devices market is being supported by the growing prevalence of cardiovascular diseases, the development of specialized cardiac care facilities, and substantial government spending aimed at modernizing healthcare infrastructure. According to the World Heart Federation, cardiovascular disease represents the leading cause of mortality across the Middle East and North Africa, accounting for more than one-third of all deaths, equivalent to approximately 1.4 million deaths annually. The proportion of deaths attributable to cardiovascular disease varies considerably across the region, ranging from around 40% in Oman to approximately 10% in Somalia.

The substantial cardiovascular disease burden is creating greater demand for advanced diagnostic technologies, including endomyocardial biopsy devices, particularly for the evaluation of cardiomyopathies, myocarditis, and transplant rejection. Regulatory authorities such as the Saudi Food and Drug Authority (SFDA) and the UAE Ministry of Health and Prevention (MOHAP) are improving regulatory processes and increasingly harmonizing requirements with international medical device standards. At the same time, the development of tertiary cardiac hospitals in Saudi Arabia, the UAE, and Qatar, combined with the region's expanding medical tourism sector, is improving access to sophisticated cardiac procedures.

The growing presence of international medical device manufacturers, including Abbott Laboratories, Medtronic plc, and Boston Scientific Corporation, is also supporting market development. In addition, professional organizations such as the Gulf Heart Association are contributing to clinical education and procedural expertise. Together, these factors are encouraging the adoption of minimally invasive, catheter-based biopsy technologies throughout the Middle East and Africa.

Strategic Insights

Middle East and Africa Endomyocardial Biopsy Devices Market Segmentation Analysis

By Product Type, the Middle East and Africa Endomyocardial Biopsy Devices Market is categorized into Biopsy Forceps and Catheters, Guidance Systems, and Accessories. The Biopsy Forceps and Catheters segment held the largest market share in 2025.

By Biopsy Forceps and Catheters, the market is divided into Standard Endomyocardial Biopsy Forceps and Flexible Biopsy Catheters. The Standard Endomyocardial Biopsy Forceps segment dominated the market in 2025.

By Guidance Systems, the market is segmented into Fluoroscopy-guided Systems, Echocardiography-guided Systems, and Emerging Robotic Navigation Systems. The Fluoroscopy-guided Systems segment accounted for the leading share in 2025.

By Accessories, the market includes Introducer Sheaths, Guidewires, and Localization Tools. The Introducer Sheaths segment represented the dominant share in 2025.

By Guidance Technique, the market is classified into Fluoroscopy-guided EMB, Echocardiography-guided EMB, and Hybrid Techniques. The Fluoroscopy-guided EMB segment led the market in 2025.

By Application, the market is segmented into Transplant Rejection Monitoring, Myocarditis Diagnosis, Cardiomyopathy Evaluation, and Other Cardiac Pathologies. The Transplant Rejection Monitoring segment held the largest market share in 2025.

By End User, the market is categorized into Cardiac Centers and Hospitals, Diagnostic and Research Institutes, and Academic Institutions. The Cardiac Centers and Hospitals segment dominated the market in 2025.

Market Report Scope

Middle East and Africa Endomyocardial Biopsy Devices Market Outlook

The integration of advanced molecular diagnostics and biomarker-based testing with endomyocardial biopsy specimens is creating new opportunities in cardiac pathology. This development is moving EMB beyond conventional histological examination toward a more comprehensive molecular assessment of cardiovascular diseases. Traditionally, the diagnostic effectiveness of endomyocardial biopsy has been constrained by sampling limitations and the subjective interpretation of tissue morphology. In some cases, conventional histology primarily identifies advanced pathological changes, including fibrosis and myocardial hypertrophy, without fully establishing the underlying cause of disease.

The incorporation of technologies such as next-generation sequencing (NGS), microarray analysis, and polymerase chain reaction (PCR) into biopsy-based workflows can provide deeper information regarding genetic, transcriptomic, and infectious causes of cardiomyopathies. For patients suspected of having myocarditis, molecular testing may assist in identifying specific viral pathogens. Similarly, patients with unexplained heart failure may benefit from genetic analysis capable of identifying mutations associated with inherited cardiomyopathies.

These molecular insights can facilitate a shift away from generalized treatment strategies toward more personalized approaches. Depending on the underlying diagnosis, this could include targeted antiviral treatments or interventions designed around specific genetic abnormalities. Consequently, the combination of tissue sampling and molecular characterization is increasing the potential clinical value of EMB procedures.

From a commercial perspective, combining a physical biopsy device, such as a bioptome, with specialized diagnostic testing services can create additional value for both device manufacturers and diagnostic companies. The growing recognition of molecular information in treatment planning and prognosis is particularly relevant to heart transplant rejection monitoring. Gene-expression profiling, for example, has the potential to identify rejection-related changes before conventional histological abnormalities become apparent.

As the clinical benefits of integrated molecular and tissue-based diagnostics become more established, reimbursement frameworks may increasingly support these combined approaches. Improved reimbursement can encourage healthcare institutions to invest in specialized infrastructure, personnel training, and associated diagnostic capabilities, potentially increasing EMB procedure volumes.

The market is also witnessing increased collaboration between medical device manufacturers and molecular diagnostics companies. These partnerships are focused on developing integrated workflows that connect tissue acquisition with genomic and molecular analysis. Such developments can simplify clinical processes while strengthening the position of endomyocardial biopsy as an important component of data-driven and precision-oriented cardiac care.

Middle East and Africa Endomyocardial Biopsy Devices Market Country Insights

By country, the Middle East and Africa Endomyocardial Biopsy Devices Market is segmented into Saudi Arabia, South Africa, the United Arab Emirates, and the Rest of Middle East and Africa. Saudi Arabia accounted for the largest market share in 2025.

Saudi Arabia's endomyocardial biopsy devices market is benefiting from substantial public-sector healthcare investment, the rising prevalence of cardiovascular diseases, and the rapid development of specialized cardiac facilities under national initiatives such as Vision 2030. Cardiovascular diseases remain a major contributor to mortality in the country, increasing the need for reliable myocardial diagnostic procedures, particularly within tertiary and quaternary healthcare institutions.

The Saudi Food and Drug Authority (SFDA) oversees medical device regulation and has established structured regulatory requirements that increasingly correspond with international standards. These measures are improving the regulatory environment for advanced catheter-based and minimally invasive medical technologies.

Major healthcare institutions, including King Faisal Specialist Hospital and Research Centre and King Abdulaziz Medical City, are strengthening their interventional cardiology capabilities. This expansion includes advanced diagnostic procedures that can support the evaluation of cardiomyopathies and monitoring of patients following cardiac transplantation.

Professional organizations such as the Gulf Heart Association and Saudi Heart Association are contributing to the development of clinical guidelines, professional training, and awareness surrounding advanced cardiac procedures. Meanwhile, multinational companies including GE HealthCare, Siemens Healthineers, Medtronic plc, and Abbott Laboratories are supplying advanced imaging technologies and catheter-based medical devices to the Saudi healthcare market.

The expansion of medical tourism, increasing participation from private healthcare providers, and growing investment in artificial intelligence-enabled cardiac diagnostics are additional factors expected to support the development of the endomyocardial biopsy devices market in Saudi Arabia.

Middle East and Africa Endomyocardial Biopsy Devices Market Company Profiles

Major companies operating in the Middle East and Africa Endomyocardial Biopsy Devices Market include Terumo Corp, Argon Medical Devices, Koninklijke Philips NV, GE HealthCare Technologies Inc., Siemens Healthineers AG, Cordis Corp, Scholten Surgical Instruments, Inc., Changzhou Lookmed Medical Instrument Co., Ltd., FEHLING INSTRUMENTS GmbH, and WILDmedical GmbH.

These companies are pursuing multiple strategies, including geographic expansion, product innovation, strategic partnerships, mergers, and acquisitions. Such initiatives are intended to expand product portfolios, introduce advanced technologies, address changing clinical requirements, strengthen regional presence, and increase overall market share.

Product Code: TIPRE00043896

1. Executive Summary

1.1 Analyst Market Outlook

2. Global Endomyocardial Biopsy Devices Market Landscape

2.1 Overview
2.2 Value Chain Analysis
2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
2.4 Porter's Five Forces Analysis
2.5 PEST Analysis

3. Competitive Landscape

3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2025 - By Key Players
3.3 Market Concentration

4. Middle East and Africa Endomyocardial Biopsy Devices Market - Key Industry Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints:

5. Endomyocardial Biopsy Devices Market - Middle East and Africa Analysis

5.1 Middle East and Africa Endomyocardial Biopsy Devices Market Revenue (US$ Thousand), 2021 - 2034
5.2 Middle East and Africa Endomyocardial Biopsy Devices Market Revenue Forecast and Analysis

6. Middle East and Africa Endomyocardial Biopsy Devices Market Revenue Analysis - by Product Type

6.1 Middle East and Africa Endomyocardial Biopsy Devices Market Forecast and Analysis by Product Type
- 6.1.1 Biopsy Forceps and Catheters
  - 6.1.1.1 Overview
  - 6.1.1.2 Biopsy Forceps and Catheters: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 6.1.2 Guidance Systems
  - 6.1.2.1 Overview
  - 6.1.2.2 Guidance Systems: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 6.1.3 Accessories
  - 6.1.3.1 Overview
  - 6.1.3.2 Accessories: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

7. Middle East and Africa Endomyocardial Biopsy Devices Market Revenue Analysis - by Biopsy Forceps And Catheters

7.1 Middle East and Africa Endomyocardial Biopsy Devices Market Forecast and Analysis by Biopsy Forceps And Catheters
- 7.1.1 Standard endomyocardial biopsy forceps
  - 7.1.1.1 Overview
  - 7.1.1.2 Standard endomyocardial biopsy forceps: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 7.1.2 Flexible biopsy catheters
  - 7.1.2.1 Overview
  - 7.1.2.2 Flexible biopsy catheters: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

8. Middle East and Africa Endomyocardial Biopsy Devices Market Revenue Analysis - by Guidance Systems - Product Type

8.1 Middle East and Africa Endomyocardial Biopsy Devices Market Forecast and Analysis by Guidance Systems - Product Type
- 8.1.1 Fluoroscopy-guided systems
  - 8.1.1.1 Overview
  - 8.1.1.2 Fluoroscopy-guided systems: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 8.1.2 Echocardiography-guided systems
  - 8.1.2.1 Overview
  - 8.1.2.2 Echocardiography-guided systems: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 8.1.3 Emerging robotic navigation systems
  - 8.1.3.1 Overview
  - 8.1.3.2 Emerging robotic navigation systems: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

9. Middle East and Africa Endomyocardial Biopsy Devices Market Revenue Analysis - by Accessories

9.1 Middle East and Africa Endomyocardial Biopsy Devices Market Forecast and Analysis by Accessories
- 9.1.1 Introducer sheaths
  - 9.1.1.1 Overview
  - 9.1.1.2 Introducer sheaths: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 9.1.2 Guidewires
  - 9.1.2.1 Overview
  - 9.1.2.2 Guidewires: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 9.1.3 Localization tools
  - 9.1.3.1 Overview
  - 9.1.3.2 Localization tools: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

10. Middle East and Africa Endomyocardial Biopsy Devices Market Revenue Analysis - by Guidance Technique

10.1 Middle East and Africa Endomyocardial Biopsy Devices Market Forecast and Analysis by Guidance Technique
- 10.1.1 Fluoroscopy-guided EMB
  - 10.1.1.1 Overview
  - 10.1.1.2 Fluoroscopy-guided EMB: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 10.1.2 Echocardiography-guided EMB
  - 10.1.2.1 Overview
  - 10.1.2.2 Echocardiography-guided EMB: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 10.1.3 Hybrid techniques
  - 10.1.3.1 Overview
  - 10.1.3.2 Hybrid techniques: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

11. Middle East and Africa Endomyocardial Biopsy Devices Market Revenue Analysis - by Application

11.1 Middle East and Africa Endomyocardial Biopsy Devices Market Forecast and Analysis by Application
- 11.1.1 Transplant rejection monitoring
  - 11.1.1.1 Overview
  - 11.1.1.2 Transplant rejection monitoring: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 11.1.2 Myocarditis diagnosis
  - 11.1.2.1 Overview
  - 11.1.2.2 Myocarditis diagnosis: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 11.1.3 Cardiomyopathy evaluation
  - 11.1.3.1 Overview
  - 11.1.3.2 Cardiomyopathy evaluation: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 11.1.4 Other cardiac pathologies
  - 11.1.4.1 Overview
  - 11.1.4.2 Other cardiac pathologies: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

12. Middle East and Africa Endomyocardial Biopsy Devices Market Revenue Analysis - by End User

12.1 Middle East and Africa Endomyocardial Biopsy Devices Market Forecast and Analysis by End User
- 12.1.1 Cardiac centers and hospitals
  - 12.1.1.1 Overview
  - 12.1.1.2 Cardiac centers and hospitals: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 12.1.2 Diagnostic and research institutes
  - 12.1.2.1 Overview
  - 12.1.2.2 Diagnostic and research institutes: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 12.1.3 Academic institutions
  - 12.1.3.1 Overview
  - 12.1.3.2 Academic institutions: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

13. Middle East and Africa Endomyocardial Biopsy Devices Market - Country Analysis

13.1 Middle East and Africa
- 13.1.1 Middle East and Africa Endomyocardial Biopsy Devices Market Forecast and Analysis - by Country
  - 13.1.1.1 Saudi Arabia Market
    - 13.1.1.1.1 Saudi Arabia: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
    - 13.1.1.1.2 Saudi Arabia: Middle East and Africa Endomyocardial Biopsy Devices Market - By Segmentation
      - 13.1.1.1.2.1 Product Type
      - 13.1.1.1.2.2 Biopsy Forceps And Catheters
      - 13.1.1.1.2.3 Guidance Systems - Product Type
      - 13.1.1.1.2.4 Accessories
      - 13.1.1.1.2.5 Guidance Technique
      - 13.1.1.1.2.6 Application
      - 13.1.1.1.2.7 End User
  - 13.1.1.2 South Africa Market
    - 13.1.1.2.1 South Africa: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
    - 13.1.1.2.2 South Africa: Middle East and Africa Endomyocardial Biopsy Devices Market - By Segmentation
      - 13.1.1.2.2.1 Product Type
      - 13.1.1.2.2.2 Biopsy Forceps And Catheters
      - 13.1.1.2.2.3 Guidance Systems - Product Type
      - 13.1.1.2.2.4 Accessories
      - 13.1.1.2.2.5 Guidance Technique
      - 13.1.1.2.2.6 Application
      - 13.1.1.2.2.7 End User
  - 13.1.1.3 United Arab Emirates Market
    - 13.1.1.3.1 United Arab Emirates: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
    - 13.1.1.3.2 United Arab Emirates: Middle East and Africa Endomyocardial Biopsy Devices Market - By Segmentation
      - 13.1.1.3.2.1 Product Type
      - 13.1.1.3.2.2 Biopsy Forceps And Catheters
      - 13.1.1.3.2.3 Guidance Systems - Product Type
      - 13.1.1.3.2.4 Accessories
      - 13.1.1.3.2.5 Guidance Technique
      - 13.1.1.3.2.6 Application
      - 13.1.1.3.2.7 End User
  - 13.1.1.4 Rest of Middle East and Africa Market
    - 13.1.1.4.1 Rest of Middle East and Africa: Middle East and Africa Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
    - 13.1.1.4.2 Rest of Middle East and Africa: Middle East and Africa Endomyocardial Biopsy Devices Market - By Segmentation
      - 13.1.1.4.2.1 Product Type
      - 13.1.1.4.2.2 Biopsy Forceps And Catheters
      - 13.1.1.4.2.3 Guidance Systems - Product Type
      - 13.1.1.4.2.4 Accessories
      - 13.1.1.4.2.5 Guidance Technique
      - 13.1.1.4.2.6 Application
      - 13.1.1.4.2.7 End User

14 Endomyocardial Biopsy Devices Market Industry Landscape

15 - Key Company Profiles

15.1 Terumo Corp
- 15.1.1 Key Facts
- 15.1.2 Business Description
- 15.1.3 Products and Services
- 15.1.4 Financial Overview
- 15.1.5 SWOT Analysis
- 15.1.6 Key Developments
15.2 Argon Medical Devices
- 15.2.1 Key Facts
- 15.2.2 Business Description
- 15.2.3 Products and Services
- 15.2.4 Financial Overview
- 15.2.5 SWOT Analysis
- 15.2.6 Key Developments
15.3 Koninklijke Philips NV
- 15.3.1 Key Facts
- 15.3.2 Business Description
- 15.3.3 Products and Services
- 15.3.4 Financial Overview
- 15.3.5 SWOT Analysis
- 15.3.6 Key Developments
15.4 GE HealthCare Technologies Inc
- 15.4.1 Key Facts
- 15.4.2 Business Description
- 15.4.3 Products and Services
- 15.4.4 Financial Overview
- 15.4.5 SWOT Analysis
- 15.4.6 Key Developments
15.5 Siemens Healthineers AG
- 15.5.1 Key Facts
- 15.5.2 Business Description
- 15.5.3 Products and Services
- 15.5.4 Financial Overview
- 15.5.5 SWOT Analysis
- 15.5.6 Key Developments
15.6 Cordis Corp
- 15.6.1 Key Facts
- 15.6.2 Business Description
- 15.6.3 Products and Services
- 15.6.4 Financial Overview
- 15.6.5 SWOT Analysis
- 15.6.6 Key Developments
15.7 Scholten Surgical Instruments, Inc.
- 15.7.1 Key Facts
- 15.7.2 Business Description
- 15.7.3 Products and Services
- 15.7.4 Financial Overview
- 15.7.5 SWOT Analysis
- 15.7.6 Key Developments
15.8 Changzhou Lookmed Medical Instrument Co., Ltd.
- 15.8.1 Key Facts
- 15.8.2 Business Description
- 15.8.3 Products and Services
- 15.8.4 Financial Overview
- 15.8.5 SWOT Analysis
- 15.8.6 Key Developments
15.9 FEHLING INSTRUMENTS GmbH
- 15.9.1 Key Facts
- 15.9.2 Business Description
- 15.9.3 Products and Services
- 15.9.4 Financial Overview
- 15.9.5 SWOT Analysis
- 15.9.6 Key Developments
15.10 WILDmedical GmbH
- 15.10.1 Key Facts
- 15.10.2 Business Description
- 15.10.3 Products and Services
- 15.10.4 Financial Overview
- 15.10.5 SWOT Analysis
- 15.10.6 Key Developments

16. Appendix

16.1 Glossary
16.2 Research Methodology and Approach
- 16.2.1 Secondary Research
- 16.2.2 Primary Research
- 16.2.3 Market Estimation Approach
  - 16.2.3.1 Supply Side Analysis
  - 16.2.3.2 Demand Side Analysis
- 16.2.4 Research Assumptions and Limitations
- 16.2.5 Currency Conversion
16.3 About The Insight Partners
16.4 Market Intelligence Cloud